4-Antibody AG Meets Milestone in Boehringer Ingelheim Collaboration

Please login or
register
23.09.2011

4-Antibody AG today announced the successful completion of a second milestone in its ongoing collaboration with Boehringer Ingelheim. This second milestone triggered an undisclosed fee payment.

4-Antibody’s R&D collaboration with Boehringer Ingelheim commenced in early 2010 and is a long-term collaboration to discover and develop fully human therapeutic antibodies for a number of targets in various disease indications. The collaboration centres on 4-Antibody’s proprietary high throughput in vitro Retrocyte Display® technology for rapid antibody discovery and development of fully human antibodies against novel targets nominated by Boehringer Ingelheim.

Robert Burns, 4-Antibody’s CEO, said: “Not only do you want your collaborations to serve an important role in validating your technology, but you also want your partners to be sufficiently happy that they continue to pay milestone payments as successful programme targets are achieved. We set out with our high throughput in vitro Retrocyte Display® technology to show we can take all the advantages of in vivo as well as in vitro platforms and combine them both without the limitations of these existing approaches. We see our continued partnering success as confirmation of that strategy.”

0Comments

More news about

4-Antibody

Company profiles on startup.ch

4-Antibody

rss